IRIS
MONTELEONE, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 85.424
AS - Asia 11.675
EU - Europa 8.915
SA - Sud America 1.624
Continente sconosciuto - Info sul continente non disponibili 1.340
AF - Africa 202
OC - Oceania 28
Totale 109.208
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 84.867
SG - Singapore 5.701
CN - Cina 2.192
IT - Italia 1.867
BR - Brasile 1.322
RU - Federazione Russa 1.169
HK - Hong Kong 1.163
DE - Germania 1.054
UA - Ucraina 949
IE - Irlanda 832
VN - Vietnam 799
BD - Bangladesh 598
FI - Finlandia 586
GB - Regno Unito 581
FR - Francia 547
SE - Svezia 437
PL - Polonia 300
CA - Canada 276
JP - Giappone 260
KR - Corea 251
IN - India 147
NL - Olanda 128
AR - Argentina 100
MX - Messico 95
ID - Indonesia 94
ES - Italia 77
TR - Turchia 68
AT - Austria 66
BE - Belgio 66
IQ - Iraq 66
ZA - Sudafrica 62
EC - Ecuador 46
CO - Colombia 43
JM - Giamaica 40
CR - Costa Rica 35
LT - Lituania 35
CH - Svizzera 34
PK - Pakistan 33
SA - Arabia Saudita 33
CL - Cile 32
VE - Venezuela 28
PH - Filippine 27
PY - Paraguay 25
RO - Romania 25
AU - Australia 24
TN - Tunisia 24
UZ - Uzbekistan 24
MY - Malesia 22
EG - Egitto 21
IL - Israele 21
CZ - Repubblica Ceca 20
EE - Estonia 20
MA - Marocco 20
TT - Trinidad e Tobago 19
HN - Honduras 17
AE - Emirati Arabi Uniti 16
IR - Iran 16
GR - Grecia 15
JO - Giordania 15
KZ - Kazakistan 15
NP - Nepal 14
SC - Seychelles 14
TH - Thailandia 14
DK - Danimarca 13
DZ - Algeria 13
EU - Europa 13
KE - Kenya 13
NG - Nigeria 13
AZ - Azerbaigian 12
DO - Repubblica Dominicana 12
KG - Kirghizistan 12
NI - Nicaragua 12
NO - Norvegia 10
PE - Perù 10
SV - El Salvador 10
TW - Taiwan 10
AL - Albania 9
RS - Serbia 9
UY - Uruguay 9
BG - Bulgaria 8
LB - Libano 8
PT - Portogallo 8
ET - Etiopia 7
PA - Panama 7
BB - Barbados 6
GT - Guatemala 6
LK - Sri Lanka 6
MD - Moldavia 6
DM - Dominica 5
HU - Ungheria 5
MK - Macedonia 5
OM - Oman 5
PR - Porto Rico 5
PS - Palestinian Territory 5
SI - Slovenia 5
SK - Slovacchia (Repubblica Slovacca) 5
A1 - Anonimo 4
BH - Bahrain 4
BO - Bolivia 4
BS - Bahamas 4
Totale 107.805
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.561
Wilmington 18.741
Houston 18.094
Singapore 2.750
Fairfield 2.605
Ashburn 2.511
Ann Arbor 2.020
San Jose 1.742
Chandler 1.282
Hong Kong 1.139
Seattle 1.064
Council Bluffs 877
Cambridge 863
Jacksonville 840
Beijing 815
Dublin 743
Santa Clara 604
Medford 593
Rome 573
Dearborn 454
New York 444
The Dalles 414
Los Angeles 384
Helsinki 353
Lawrence 273
Ho Chi Minh City 234
Kraków 221
Tokyo 221
Buffalo 216
Hanoi 197
Dallas 188
Lauterbourg 180
Milan 176
Boardman 168
Moscow 165
San Diego 157
Zhengzhou 155
Chicago 136
São Paulo 133
North Charleston 122
Menlo Park 120
London 108
Monte Vista 102
Denver 100
Mülheim 97
Atlanta 87
Phoenix 83
Nuremberg 80
Brooklyn 78
North Bergen 78
Montreal 72
Munich 70
Warsaw 66
Orem 65
Redondo Beach 63
Rio de Janeiro 62
Brussels 60
Redwood City 60
Shanghai 60
Toronto 58
Jakarta 57
Seoul 54
Mountain View 52
Columbus 51
Chennai 47
Frankfurt am Main 47
Colorado Springs 45
Norwalk 44
Johannesburg 43
Verona 43
Naples 42
San Mateo 41
Miami 39
Washington 37
Vienna 36
University Park 35
Da Nang 34
Philadelphia 34
San Francisco 34
Belo Horizonte 33
Indianapolis 33
Baghdad 32
Brasília 32
Guangzhou 32
Hangzhou 32
Lappeenranta 32
Palo Alto 32
Amsterdam 31
Boston 31
Las Vegas 31
Falls Church 30
Haiphong 30
Manchester 30
New Orleans 28
Detroit 27
Hefei 27
Stockholm 27
Bologna 26
Kingston 26
Nanjing 26
Totale 87.420
Salva come PNG Salva come JPEG
Nome #
Appropriate nutrient supplementation in celiac disease 692
Pyoderma gangrenosum in refractory celiac disease: a case report 628
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells 623
2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression 603
A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction 600
2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms 585
A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis 570
Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut 563
Aryl hydrocarbon receptor and colitis 549
Frequency and cause of persistent symptoms in celiac disease patients on a long-term gluten-free diet 549
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract 533
Interleukin-34 sustains inflammatory pathways in the gut 532
Regulation of gut inflammation and Th17 cell response by interleukin-21 529
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 518
Breast milk lactoferrin regulates gene expression by binding bacterial DNA CpG motifs but not genomic DNA promoters in model intestinal cells 516
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth 516
TNF-α producing innate lymphoid cells (ILCs) are increased in active celiac disease and contribute to promote intestinal atrophy in mice 513
Role of interleukin-21 in inflammation and allergy 512
Characterization of IL-17A-producing cells in celiac disease mucosa 512
Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa 511
5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death 509
High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases 504
IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN- -Dependent Epidermal Hyperplasia 504
Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation 498
IL-21 comes of age as a regulator of effector T cells in the gut 497
Distinct profiles of effector cytokines mark the different phases of Crohn's disease 497
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid 496
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies 496
No change in the mucosal gut microbiome is associated with celiac disease-specific microbiome alteration in adult patients 495
Colorectal cancer chemoprevention by mesalazine and its derivatives 491
Local immune activity in acute coronary syndrome: oxLDL abrogates LPS-tolerance in mononuclear cells isolated from culprit lesion 491
Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells 491
The gut-skin axis in health and disease: A paradigm with therapeutic implications 489
High Smad7 sustains inflammatory cytokine response in refractory coeliac disease 489
The dual role of Smad7 in the control of cancer growth and metastasis 488
Smad7 knockdown restores aryl hydrocarbon receptor-mediated protective signals in the gut 487
Lactobacillus paracasei subsp paracasei B21060 suppresses human T-cell proliferation 485
Activated STAT4 and a functional role for IL-12 in human Peyer's patches 483
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 483
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3 482
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes 480
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease 479
Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection 479
An overview of the role of innate lymphoid cells in gut infections and inflammation 479
Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection 478
Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells 478
Collagen matrix injection combined with flap repair for complex anal fistula 478
Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients 478
The Dual Role of Interleukin-25 in the Control of Immune-Mediated Pathologies 478
Aryl hydrocarbon receptor-driven signals inhibit collagen synthesis in the gut 478
Autocrine regulation of IL-21 production in human T lymphocytes 476
Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease 476
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 476
IL-21 regulates experimental colitis by modulating the balance between T-reg and Th17 cells 475
Smad7 Expression in T cells Prevents Colitis-Associated Cancer 475
TGF-Beta signaling manipulation as potential therapy for IBD 475
IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity 475
Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies 475
Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease 475
Interleukin-25 Inhibits Interleukin-12 Production and Th1 Cell-Driven Inflammation in the Gut 474
Peritoneal expression of matrilysin helps identify early post-operative recurrence of colorectal cancer 474
Tofacitinib for the treatment of ulcerative colitis 473
Immunity, inflammation, and allergy in the gut 472
Targeting interleukin-21 in immune-mediated pathologies 472
Sampling of proximal and distal duodenal biopsies in the diagnosis and monitoring of celiac disease 472
Celiac disease-related inflammation is marked by reduction of Nkp44/Nkp46-double positive natural killer cells 472
Bacteria and mucosal immunity 471
Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy 471
A Functional Role of Flip in Conferring Resistance of Crohn’s Disease Lamina Propria Lymphocytes to FAS-Mediated Apoptosis 469
Interleukin-34 induces Cc-chemokine ligand 20 in gut epithelial cells 469
Erratum: A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction (Cell Reports (2016) 16(3) (731–743) (S2211124716307677) (10.1016/j.celrep.2016.06.027)) 469
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T-reg cells via regulation of MIP-3 alpha 468
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3 alpha, by gut epithelial cells 468
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation 468
Plasma cells in the mucosa of patients with inflammatory bowel disease produce granzyme B and possess cytotoxic activities 467
Antisense approach to inflammatory bowel disease: Prospects and challenges 463
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation 462
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide 461
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease 459
Interleukin-21 (IL-21) controls inflammatory pathways in the gut 457
The dual role of inflammation in colon carcinogenesis 457
Helicobacter pylori infection associates with a mucosal downregulation of Ghrelin, negative regulator of Th1-cell responses 457
IL-21 in the pathogenesis and treatment of skin diseases 456
CARD15 mutation analysis in an Italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease 456
Interleukin-12 drives the Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa 455
Role of Smad7 in inflammatory bowel diseases 454
Emerging immunological targets in inflammatory bowel disease 454
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease 454
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages 453
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase 450
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target 450
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa 449
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer 449
Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures 448
Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer 448
TGF-beta 1 and Smad7 in the regulation of IBD 447
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine 447
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis 447
New players in the cytokine orchestra of inflammatory bowel disease 446
Cutting edge: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25- T cells 446
Totale 48.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 277.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 277.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.434 0 0 0 167 81 256 131 115 382 289 209 804
2022/20233.467 353 294 67 430 323 795 292 224 325 74 198 92
2023/20241.243 154 42 85 43 125 250 77 205 19 19 32 192
2024/20258.675 225 1.660 934 532 191 775 530 369 816 704 1.140 799
2025/202615.145 1.040 636 1.443 1.151 1.293 669 1.734 1.713 1.628 1.422 1.451 965
2026/20275.946 1.164 1.069 2.857 856 0 0 0 0 0 0 0 0
Totale 109.208